[1] |
Ferlay J, Colombet M, Soerjomataram I , et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953.
doi: 10.1002/ijc.31937
URL
pmid: 30350310
|
[2] |
Hussein AA, Helder MN, de Visscher JG, et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review[J]. Eur J Cancer, 2017,82:115-127.
doi: 10.1016/j.ejca.2017.05.026
URL
pmid: 28654785
|
[3] |
De Paz D, Kao HK, Huang Y , et al. Prognostic stratification of patients with advanced oral cavity squamous cell carcinoma[J]. Curr Oncol Rep, 2017,19(10):65.
doi: 10.1007/s11912-017-0624-3
URL
pmid: 28799122
|
[4] |
Kim KH, Roberts CW . Targeting EZH2 in cancer[J]. Nat Med, 2016,22(2):128-134.
doi: 10.1038/nm.4036
URL
pmid: 26845405
|
[5] |
Li Z, Wang Y, Qiu J , et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer[J]. Oncotarget, 2013,4(12):2532-2549.
|
[6] |
Shen L, Cui J, Liang SM , et al. Update of research on the role of EZH2 in cancer progression[J]. Onco Targets Ther, 2013,6:321-324.
doi: 10.2147/OTT.S42453
URL
pmid: 23589697
|
[7] |
Huang X, Yan J, Zhang M , et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors[J]. Cell, 2018,175(1):186-199.
doi: 10.1016/j.cell.2018.08.058
URL
pmid: 30220457
|
[8] |
Almangush A, Coletta RD, Bello IO , et al. A simple novel prognostic model for early stage oral tongue cancer[J]. Int J Oral Maxillofac Surg, 2015,44(2):143-150.
doi: 10.1016/j.ijom.2014.10.004
URL
pmid: 25457829
|
[9] |
Tang QM, Cheng B, Xie MR , et al. Circadian clock gene bmal1 inhibits tumorigenesis and increases paclitaxel sensitivity in tongue squamous cell carcinoma[J]. Cancer Res, 2017,77(2):532-544.
doi: 10.1158/0008-5472.CAN-16-1322
URL
pmid: 27821487
|
[10] |
Zeng DL, Liu MX, Pan JX . Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells[J]. Oncotarget, 2017,8(2):3396-3411.
doi: 10.18632/oncotarget.13773
URL
pmid: 27926488
|
[11] |
Wu C, Jin X, Yang J , et al. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer[J]. Oncotarget, 2016,7(3):3440-3452.
doi: 10.18632/oncotarget.6497
URL
pmid: 26657505
|
[12] |
Gulati N, Béguelin W, Giulino-Roth L . Enhancer of zeste homolog 2 (EZH2) inhibitors[J]. Leuk Lymphoma, 2018,59(7):1574-1585.
doi: 10.1080/10428194.2018.1430795
URL
pmid: 29473431
|
[13] |
Koppens MA, Bounova G, Cornelissen-Steijger P , et al. Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition[J]. Oncotarget, 2016,7(43):69816-69828.
doi: 10.18632/oncotarget.12002
URL
pmid: 27634879
|
[14] |
Deschênes-Simard X, Gaumont-Leclerc MF, Bourdeau V , et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation[J]. Genes Dev, 2013,27(8):900-915.
doi: 10.1101/gad.203984.112
URL
pmid: 23599344
|
[15] |
Kidger AM, Keyse SM . The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases(MKPs)[J]. Semin Cell Dev Biol, 2016,50:125-132.
doi: 10.1016/j.semcdb.2016.01.009
URL
pmid: 26791049
|
[16] |
Chan LP, Liu C, Chiang FY , et al. IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC[J]. Oncotarget, 2017,8(34):56375-56388.
doi: 10.18632/oncotarget.16914
URL
pmid: 28915597
|
[17] |
Xu XB, Lai YY, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials[J]. Biosci Rep, 2019, 39(1): BSR20180992.
doi: 10.1042/BSR20180789
URL
pmid: 30606744
|
[18] |
Bonneau B, Ando H, Kawaai K , et al. IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact[J]. Elife, 2016,5:e19896.
doi: 10.7554/eLife.19896
URL
pmid: 27995898
|
[19] |
Maes ME, Schlamp CL, Nickells RW . Live-cell imaging to measure BAX recruitment kinetics to mitochondria during apoptosis[J]. PLoS One, 2017,12(9):e0184434.
doi: 10.1371/journal.pone.0184434
URL
pmid: 28880942
|
[20] |
Li P, Zhou LB, Zhao T , et al. Caspase-9: structure, mechanisms and clinical application[J]. Oncotarget, 2017,8(14):23996-24008.
doi: 10.18632/oncotarget.15098
URL
pmid: 28177918
|
[21] |
Maes ME, Schlamp CL, Nickells RW . BAX to basics: how the BCL2 gene family controls the death of retinal ganglion cells[J]. Prog Retin Eye Res, 2017,57:1-25.
doi: 10.1016/j.preteyeres.2017.01.002
URL
pmid: 28064040
|